Journals / The Anatolian Journal of Cardiology / 2016 / Cilt: 16 - Sayı: 8

Subcutaneous defibrillator implantation in pediatric patients

Pages
630–634
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Because the high growth rate in this population leads to lead failures, a close follow-up of this population is essential.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Although sudden cardiac death is rare in children, an intracardiac defibrillator system is indicated in children with various types of cardiomyopathy, primary electrical diseases, and after surgical repair of congenital heart defects.
📊
Key Findings & Data:Subcutaneous array leads combined with an abdominally placed generator can enable implantation.Method: This is a retrospective study of 13 patients who underwent subcutaneous defibrillator implantation between September 2010 and March 2015.
💡
Conclusion & Impact:Because the high growth rate in this population leads to lead failures, a close follow-up of this population is essential.
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Although sudden cardiac death is rare in children, an intracardiac defibrillator system is indicated in children with various types of cardiomyopathy, primary electrical diseases, and after surgical repair of congenital heart defects. The use of transvenous defibrillator lead systems is limited in pediatric patients because of a small body size and/or limited vascular access. Subcutaneous array leads combined with an abdominally placed generator can enable implantation.Method: This is a retrospective study of 13 patients who underwent subcutaneous defibrillator implantation between September 2010 and March 2015. The subcutaneous system was preferred because patients were not amenable to transvenous lead placement.Results: The median patient age was 4.1 years, and the median patient weight was 12.1 kg. Diagnoses of patients were long-QT syndrome in 6, aborted cardiac arrest with left ventricular non-compaction in 3, hypertrophic cardiomyopathy with sustained ventricular tachycardia in 3, and arrythmogenic right ventricular cardiomyopathy in 1. Revision of the subcutaneous lead was required in 5 patients 2 26 months after the implantation. Appropriate shocks were observed in three patients. Inappropriate shock and lead fractures were observed in one patient during the follow-up period. The failure of therapy was observed in one patient. There were no perioperative complications and no early or late deaths.Conclusion: Subcutaneous defibrillator systems are safe and effective in pediatric patients when the transvenous method is risky and contrain-dicated. Because the high growth rate in this population leads to lead failures, a close follow-up of this population is essential.

🔖

Cite This Article

ERTUĞRUL, İ., KARAGÖZ, T., AYKAN, H., YILDIRIM, I., ÖZER, S., KARAGÖZ, H., YILMAZ, M. (2016). Subcutaneous defibrillator implantation in pediatric patients. The Anatolian Journal of Cardiology, Cilt: 16 - Sayı: 8, 630–634. https://ajindex.com/articles/365430

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Liberthson RR. Sudden death from cardiac causes in children and young adults. N Engl J Med 1996; 334: 1039-44
  2. Silka MJ, Kron J, Dunnigan A, Dick M 2nd. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The Pediatric Electrophysiology Society. Circulation 1993; 87: 800-7
  3. Bar-Cohen Y, Berul CI, Alexander ME, Fortescue EB, Walsh EP, Triedman JK, et al. Age, size, and lead factors alone do not predict venous obstruction in children and young adults with transvenous lead systems. J Cardiovasc Electrophysiol 2006; 17: 754-9
  4. Luedemann M, Hund K, Stertmann W, Michel-Behnke I, Gonzales M, Akintuerk H, et al. Implantable cardioverter defibrillator in a child using a single subcutaneous array lead and an abdominal ac-tive can. Pacing Clin Electrophysiol 2004; 27: 117-9
  5. Griksaitis MJ, Rosengarten JA, Gnanapragasam JP, Haw MP, Mor-gan JM. Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutane-ous defibrillation. Europace 2013; 15: 523-30
  6. Blom NA. Implantable cardioverter-defibrillators in children. Pac-ing Clin Electrophysiol 2008; 31: 32-4
  7. Cannon BC, Friedman RA, Fenrich AL, Fraser CD, McKenzie ED, Kertesz NJ. Innovative techniques for placement of implantable cardioverter-defibrillator leads in patients with limited venous ac-cess to the heart. Pacing Clin Electrophysiol 2006; 29: 181-7
  8. Thogersen AM, Helvind M, Jensen T, Andersen JH, Jacobsen JR, Chen X. Implantable cardioverter defibrillator in a 4-month-old in-fant with cardiac arrest associated with a vascular heart tumor. Pacing Clin Electrophysiol 2001; 24: 1699-700
  9. Stephenson EA, Batra AS, Knilans TK, Gow RM, Gradaus R, Balaji S, et al. A multicenter experience with novel implantable cardio-verter defibrillator configurations in the pediatric and congenital heart disease population. J Cardiovasc Electrophysiol 2006; 17: 41-6
  10. Tomaske M, Prêtre R, Rahn M, Bauersfeld U. Epicardial and pleural lead ICD systems in children and adolescents maintain functional-ity over 5 years. Europace 2008; 10: 1152-6
  11. Hadano Y, Ogawa H, Wakeyama T, Takaki A, Iwami T, Kimura M, et al. Defibrillation efficacy of a subcutaneous array lead: A case report. JC Cases 2010; 1: 21-4
  12. Alexander ME, Cecchin F, Walsh EP, Triedman JK, Bevilacqua LM, Berul CI. Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics. J Cardiovasc Ele